Logistic regression analysis of the risk of myopathy for cerivastatin with concurrent gemfibrozil compared to cerivastatin monotherapy (adjusting for age, gender, diabetes, switching and dose) gave an adjusted odds ratio of 25.5 with a 95% confidence interval of 12.9 to 50.3.